Class Action Filed Against ADMA Biologics for Securities Violations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 12 2026
0mins
Source: Globenewswire
- Lawsuit Background: Bronstein, Gewirtz & Grossman has filed a class action lawsuit against ADMA Biologics, alleging violations of federal securities laws during the period from August 9, 2024, to March 25, 2026, affecting all investors who purchased ADMA securities during this timeframe.
- Allegations: The complaint claims that ADMA Biologics engaged in undisclosed related party transactions, utilized channel stuffing to inflate revenue, and lacked adequate internal controls, resulting in materially false and misleading statements regarding its business, operations, and prospects.
- Investor Action: Affected investors have until August 10, 2026, to request appointment as lead plaintiff in the case, allowing them to seek compensation without needing to serve as lead plaintiff to share in any recovery.
- Law Firm's Advantage: Bronstein, Gewirtz & Grossman operates on a contingency fee basis and has successfully recovered hundreds of millions for investors nationwide, focusing on restoring investor capital and ensuring corporate accountability to uphold market integrity.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADMA
About ADMA
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Class Action Filed Against ADMA Biologics for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against ADMA Biologics, aiming to recover damages for investors who purchased securities between August 9, 2024, and March 25, 2026, highlighting significant investor concern over potential violations by the company.
- Detailed Allegations: The complaint alleges that ADMA Biologics engaged in undisclosed related party transactions, utilized channel stuffing to create a false appearance of revenue, and lacked adequate internal controls, indicating serious deficiencies in the company's operational transparency and compliance that could undermine investor confidence.
- Investor Action Call: Affected investors are encouraged to apply to be lead plaintiffs by August 10, 2026, suggesting that the legal risks faced by the company may impact its future stock performance, necessitating close monitoring of the case's developments.
- Law Firm Background: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that has recovered hundreds of millions for investors, emphasizing its expertise in securities fraud class actions, which may bolster investor confidence in the case's potential outcomes.
See More
ADMA Biologics Faces Class Action Lawsuit
- Class Action Initiation: ADMA Biologics is facing a class action lawsuit for alleged violations of the Securities Act during the period from August 9, 2024, to March 25, 2026, with investors needing to apply as lead plaintiffs by August 10, 2026, potentially impacting the company's reputation and stock price.
- False Statement Allegations: The lawsuit claims that ADMA Biologics failed to disclose related party transactions and engaged in channel stuffing, misleading investors about its financial health, which could lead to future legal liabilities and financial losses.
- Stock Price Volatility: Following a report from Culper Research alleging fictitious growth, ADMA's stock price dropped over 16% on March 24, 2026, and fell more than 13% again on March 26 after Cantor Fitzgerald downgraded its rating, indicating a lack of market confidence in the company.
- Law Firm Background: Robbins Geller Rudman & Dowd LLP, a leading firm in securities fraud and shareholder rights litigation, recovered over $916 million for investors in 2025, showcasing its strength in such cases, which may influence ADMA Biologics' legal strategy.
See More
ADMA Biologics Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action lawsuit against ADMA Biologics and its executives, alleging securities fraud related to a channel stuffing scheme that inflated reported 20% growth for 2025, leading to a significant stock drop and highlighting potential violations of federal securities laws.
- Stock Price Plunge: On March 24, 2026, ADMA's stock fell from $13.59 to $11.33, a 16.6% drop, with further declines in subsequent days, indicating strong investor concerns over the company's financial transparency and governance.
- False Growth Allegations: Culper Research reported that ADMA induced distributors to stockpile ASCENIV to artificially boost revenue, suggesting that without this scheme, the company would have faced a 3% revenue decline in 2025, which not only harms investor interests but could also impact future financing capabilities.
- Legal Implications: Investors have until August 10, 2026, to apply to lead the case, and if the lawsuit succeeds, it could have long-term negative effects on ADMA's financial health and market reputation, exacerbating the trust crisis surrounding its management.
See More
ADMA Biologics Shows Promising Profitability Outlook
- Profitability Growth: ADMA Biologics reported a net income of $407 million in Q1, reflecting a 22% year-over-year increase, indicating sustained profitability that is expected to enhance the company's competitive edge in the biopharmaceutical market.
- Significant Market Potential: Currently capturing only 4% of its total addressable market, ADMA is positioned for substantial growth, with the market projected to expand at a compound annual growth rate of 10% through 2033, suggesting significant revenue growth opportunities ahead.
- Optimistic Product Outlook: EyePoint Pharmaceuticals is on track to announce results from clinical trials for Duravyu, targeting wet age-related macular degeneration, with a market opportunity exceeding $15 billion, which could significantly elevate the company's market position if approved.
- Investment Risks and Rewards: Viking Therapeutics has an average price target 146% above its current share price, and while it remains unprofitable, its potential in obesity drug development makes it a focal point for investors, despite the inherent investment risks.
See More
SpaceX's $2 Trillion Valuation Faces Significant Hurdles Ahead
- SpaceX Valuation Analysis: Despite SpaceX's market cap hovering around $2 trillion, the company generated only $18.7 billion in revenue last year and posted a nearly $5 billion loss, indicating the fragility of its high valuation and making a doubling of its stock price over the next two to three years highly unlikely.
- ADMA Biologics Profit Growth: ADMA Biologics reported a net income of $407 million in Q1, up 22% year-over-year, with its flagship product Asceniv accounting for approximately 86% of total revenue, showcasing strong growth potential in the plasma-derived immunoglobulin market.
- EyePoint Pharmaceuticals Clinical Prospects: EyePoint Pharmaceuticals expects to announce top-line results for Duravyu soon, targeting wet age-related macular degeneration with a market opportunity exceeding $15 billion; analysts are overwhelmingly bullish, with a consensus price target 165% higher than the current share price.
- Viking Therapeutics Potential Breakthrough: Viking Therapeutics is conducting two Phase 3 trials for VK2735, and although it is currently unprofitable, its pipeline includes multiple promising therapies, with the average price target for the stock indicating a potential upside of 146%, reflecting significant growth potential.
See More
Notice of Class Action Lawsuit Against ADMA Biologics Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, to apply as lead plaintiffs by August 10, 2026, to participate in the filed class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that ADMA Biologics made materially false or misleading statements during the class period, including undisclosed related party transactions and channel stuffing practices, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its expertise and success in this field.
- Investor Action Recommendations: Investors can visit Rosen Law Firm's website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to protect their interests and avoid inexperienced intermediaries.
See More
Class Action Filed Against ADMA Biologics for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against ADMA Biologics, aiming to recover damages for investors who purchased securities between August 9, 2024, and March 25, 2026, highlighting significant investor concern over potential violations by the company.
- Detailed Allegations: The complaint alleges that ADMA Biologics engaged in undisclosed related party transactions, utilized channel stuffing to create a false appearance of revenue, and lacked adequate internal controls, indicating serious deficiencies in the company's operational transparency and compliance that could undermine investor confidence.
- Investor Action Call: Affected investors are encouraged to apply to be lead plaintiffs by August 10, 2026, suggesting that the legal risks faced by the company may impact its future stock performance, necessitating close monitoring of the case's developments.
- Law Firm Background: Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that has recovered hundreds of millions for investors, emphasizing its expertise in securities fraud class actions, which may bolster investor confidence in the case's potential outcomes.
See More
ADMA Biologics Faces Class Action Lawsuit
- Class Action Initiation: ADMA Biologics is facing a class action lawsuit for alleged violations of the Securities Act during the period from August 9, 2024, to March 25, 2026, with investors needing to apply as lead plaintiffs by August 10, 2026, potentially impacting the company's reputation and stock price.
- False Statement Allegations: The lawsuit claims that ADMA Biologics failed to disclose related party transactions and engaged in channel stuffing, misleading investors about its financial health, which could lead to future legal liabilities and financial losses.
- Stock Price Volatility: Following a report from Culper Research alleging fictitious growth, ADMA's stock price dropped over 16% on March 24, 2026, and fell more than 13% again on March 26 after Cantor Fitzgerald downgraded its rating, indicating a lack of market confidence in the company.
- Law Firm Background: Robbins Geller Rudman & Dowd LLP, a leading firm in securities fraud and shareholder rights litigation, recovered over $916 million for investors in 2025, showcasing its strength in such cases, which may influence ADMA Biologics' legal strategy.
See More
ADMA Biologics Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action lawsuit against ADMA Biologics and its executives, alleging securities fraud related to a channel stuffing scheme that inflated reported 20% growth for 2025, leading to a significant stock drop and highlighting potential violations of federal securities laws.
- Stock Price Plunge: On March 24, 2026, ADMA's stock fell from $13.59 to $11.33, a 16.6% drop, with further declines in subsequent days, indicating strong investor concerns over the company's financial transparency and governance.
- False Growth Allegations: Culper Research reported that ADMA induced distributors to stockpile ASCENIV to artificially boost revenue, suggesting that without this scheme, the company would have faced a 3% revenue decline in 2025, which not only harms investor interests but could also impact future financing capabilities.
- Legal Implications: Investors have until August 10, 2026, to apply to lead the case, and if the lawsuit succeeds, it could have long-term negative effects on ADMA's financial health and market reputation, exacerbating the trust crisis surrounding its management.
See More
ADMA Biologics Shows Promising Profitability Outlook
- Profitability Growth: ADMA Biologics reported a net income of $407 million in Q1, reflecting a 22% year-over-year increase, indicating sustained profitability that is expected to enhance the company's competitive edge in the biopharmaceutical market.
- Significant Market Potential: Currently capturing only 4% of its total addressable market, ADMA is positioned for substantial growth, with the market projected to expand at a compound annual growth rate of 10% through 2033, suggesting significant revenue growth opportunities ahead.
- Optimistic Product Outlook: EyePoint Pharmaceuticals is on track to announce results from clinical trials for Duravyu, targeting wet age-related macular degeneration, with a market opportunity exceeding $15 billion, which could significantly elevate the company's market position if approved.
- Investment Risks and Rewards: Viking Therapeutics has an average price target 146% above its current share price, and while it remains unprofitable, its potential in obesity drug development makes it a focal point for investors, despite the inherent investment risks.
See More
SpaceX's $2 Trillion Valuation Faces Significant Hurdles Ahead
- SpaceX Valuation Analysis: Despite SpaceX's market cap hovering around $2 trillion, the company generated only $18.7 billion in revenue last year and posted a nearly $5 billion loss, indicating the fragility of its high valuation and making a doubling of its stock price over the next two to three years highly unlikely.
- ADMA Biologics Profit Growth: ADMA Biologics reported a net income of $407 million in Q1, up 22% year-over-year, with its flagship product Asceniv accounting for approximately 86% of total revenue, showcasing strong growth potential in the plasma-derived immunoglobulin market.
- EyePoint Pharmaceuticals Clinical Prospects: EyePoint Pharmaceuticals expects to announce top-line results for Duravyu soon, targeting wet age-related macular degeneration with a market opportunity exceeding $15 billion; analysts are overwhelmingly bullish, with a consensus price target 165% higher than the current share price.
- Viking Therapeutics Potential Breakthrough: Viking Therapeutics is conducting two Phase 3 trials for VK2735, and although it is currently unprofitable, its pipeline includes multiple promising therapies, with the average price target for the stock indicating a potential upside of 146%, reflecting significant growth potential.
See More
Notice of Class Action Lawsuit Against ADMA Biologics Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, to apply as lead plaintiffs by August 10, 2026, to participate in the filed class action without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that ADMA Biologics made materially false or misleading statements during the class period, including undisclosed related party transactions and channel stuffing practices, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its expertise and success in this field.
- Investor Action Recommendations: Investors can visit Rosen Law Firm's website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to protect their interests and avoid inexperienced intermediaries.
See More
